Seagen (United States)

Recent papers from Seagen (United States)

1. Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitorCell Reports Medicine · 2026
2. Short-Read Sequencing Benchmarking with Donor-Specific Assemblies2026
3. Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a)Journal of the American College of Cardiology · 2014
4. 1158: Variable Clopidogrel Response in Pediatric Patients: A Call for MonitoringCritical Care Medicine · 2026
5. Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-upBlood Cancer Journal · 2026
6. Relevance of Classical Models and Simulation Approaches for Battery Digital TwinsECS Advances · 2025
7. Targeted Delivery of a Potent STING Agonist Payload via an Antibody–Drug Conjugate Drives Robust Antitumor Activity in Preclinical ModelsMolecular Cancer Therapeutics · 2025
8. EIPR1 variants cause a neurodevelopmental disorder with endolysosomal and dense core vesicle defectsBrain · 2025
9. Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-upBlood Cancer Journal · 2025
10. Recovery of cone-mediated vision in Lebercilin associated retinal ciliopathy after gene therapy: One-year results of a phase I/II trialMolecular Therapy · 2025
11. Putative epigenetic regulation mechanisms related to production, carcass and beef quality traits in Nelore cattleFrontiers in Genetics · 2025
12. The success of toll-like receptor 4 based vaccine adjuvantsVaccine · 2025
13. Targeted analysis of dyslexia-associated regions on chromosomes 6, 12 and 15 in large multigenerational cohortsPLoS ONE · 2025
14. Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2‐positive breast cancerBritish Journal of Pharmacology · 2025
15. A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast CancerVaccines · 2025
16. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphomaBlood · 2024
17. Botanical Bioflavonoid Composition from Scutellaria baicalensis- and Acacia catechu-Protected Mice against D-Galactose-Induced Immunosenescence, and Cyclophosphamide Induced Immune SuppressionNutrients · 2024
18. A Botanical Bioflavonoid Composition from Scutellaria baicalensis and Acacia catechu Protected Mice against D-Galactose-Induced Immunosenescence, and Cyclophosphamide Induced Immune Suppression2024
19. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.Journal of Clinical Oncology · 2024
20. CancerHallmarks.com: A tool for the enrichment analysis of the cancer hallmarks.Journal of Clinical Oncology · 2024